SillaJen and Lee’s Pharmaceutical Announce First Patient Enrolled in the PHOCUS Trial in ChinaPhase 3 Clinical Trial for Oncolytic Immunotherapy, Pexa-Vec, in Liver Cancer | Lee's Pharmaceutical